Janus kinase inhibitors for the treatment of myeloproliferative neoplasms

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.15, Iss.9, 2014-06, pp. : 1265-1276

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Janus kinase 2 inhibitors in myeloproliferative disorders

By Lucia Eugenio Recchia Anna Grazia Gentile Massimo Bossio Sabrina Vigna Ernesto Mazzone Carla Madeo Antonio Morabito Lucio Gigliotti Vincenzo Stefano Laura De Caruso Nadia Servillo Pasquale Franzese Stefania Bisconte Maria Grazia Gentile Carlo Morabito Fortunato

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 1, 2011-01 ,pp. : 41-59

Informa Healthcare

Access to resources Recommend Favorite

JAK2 inhibitors in the treatment of myeloproliferative neoplasms

By Tibes Raoul Bogenberger James M Geyer Holly L Mesa Ruben A

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 12, 2012-12 ,pp. : 1755-1774

Informa Healthcare

Access to resources Recommend Favorite

Investigational Janus kinase inhibitors

By Tam Constantine S

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 6, 2013-09 ,pp. : 687-699

Informa Healthcare

Access to resources Recommend Favorite

New JAK2 inhibitors for myeloproliferative neoplasms

By Quintáás-Cardama Alfonso Verstovsek Srdan

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 7, 2011-07 ,pp. : 961-972

Informa Healthcare

Access to resources Recommend Favorite

Interferon-Alpha in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Status and Perspectives

Current Drug Targets, Vol. 12, Iss. 3, 2011-01 ,pp. : 392-419

Bentham Science Publishers

Access to resources Recommend Favorite